Literature DB >> 21360034

Advances in translational neuropathic research: example of enantioselective pharmacokinetic-pharmacodynamic modeling of ketamine-induced pain relief in complex regional pain syndrome.

Michael Sabia1, Robert A Hirsh, Marc C Torjman, Irving W Wainer, Niti Cooper, Richard Domsky, Michael E Goldberg.   

Abstract

Historically, complex regional pain syndrome (CRPS) was poorly defined, which meant that scientists and clinicians faced much uncertainty in the study, diagnosis, and treatment of the syndrome. The problem could be attributed to a nonspecific diagnostic criteria, unknown pathophysiologic causes, and limited treatment options. The two forms of CRPS still are painful, debilitating disorders whose sufferers carry heavy emotional burdens. Current research has shown that CRPS I and CRPS II are distinctive processes, and the presence or absence of a partial nerve lesion distinguishes them apart. Ketamine has been the focus of various studies involving the treatment of CRPS; however, currently, there is incomplete data from evidence-based studies. The question as to why ketamine is effective in controlling the symptoms of a subset of patients with CRPS and not others remains to be answered. A possible explanation to this phenomenon is pharmacogenetic differences that may exist in different patient populations. This review summarizes important translational work recently published on the treatment of CRPS using ketamine. © Springer Science+Business Media, LLC 2011

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21360034      PMCID: PMC6022285          DOI: 10.1007/s11916-011-0185-3

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  42 in total

1.  Successful treatment of a nine-year case of complex regional pain syndrome type-I (reflex sympathetic dystrophy) with intravenous ketamine-infusion therapy in a warfarin-anticoagulated adult female patient.

Authors:  Ronald E Harbut; Graeme E Correll
Journal:  Pain Med       Date:  2002-06       Impact factor: 3.750

2.  The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case.

Authors:  H Takahashi; M Miyazaki; T Nanbu; H Yanagida; S Morita
Journal:  Pain       Date:  1998-04       Impact factor: 6.961

3.  Stereoselective pharmacokinetics of ketamine: R(-)-ketamine inhibits the elimination of S(+)-ketamine.

Authors:  H Ihmsen; G Geisslinger; J Schüttler
Journal:  Clin Pharmacol Ther       Date:  2001-11       Impact factor: 6.875

4.  Multi-day low dose ketamine infusion for the treatment of complex regional pain syndrome.

Authors:  Michael E Goldberg; Richard Domsky; Denise Scaringe; Robert Hirsh; Jessie Dotson; Imran Sharaf; Marc C Torjman; Robert J Schwartzman
Journal:  Pain Physician       Date:  2005-04       Impact factor: 4.965

5.  Enantioselective pharmacokinetics of (R)- and (S)-ketamine after a 5-day infusion in patients with complex regional pain syndrome.

Authors:  Michael E Goldberg; Marc C Torjman; Robert J Schwartzman; Donald E Mager; Irving W Wainer
Journal:  Chirality       Date:  2010-08-27       Impact factor: 2.437

6.  Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient.

Authors:  J L Clark; G E Kalan
Journal:  J Pain Symptom Manage       Date:  1995-05       Impact factor: 3.612

7.  Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method.

Authors:  G Geisslinger; W Hering; P Thomann; R Knoll; H D Kamp; K Brune
Journal:  Br J Anaesth       Date:  1993-06       Impact factor: 9.166

Review 8.  Complex regional pain syndrome: a review.

Authors:  Raneem Albazaz; Yew Toh Wong; Shervanthi Homer-Vanniasinkam
Journal:  Ann Vasc Surg       Date:  2008-03       Impact factor: 1.466

9.  Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations.

Authors:  J D Adams; T A Baillie; A J Trevor; N Castagnoli
Journal:  Biomed Mass Spectrom       Date:  1981-11

10.  Signs of neuropathic pain depend on signals from injured nerve fibers in a rat model.

Authors:  K Sheen; J M Chung
Journal:  Brain Res       Date:  1993-04-30       Impact factor: 3.252

View more
  5 in total

1.  What is hydroxynorketamine and what can it bring to neurotherapeutics?

Authors:  Nagendra S Singh; Carlos A Zarate; Ruin Moaddel; Michel Bernier; Irving W Wainer
Journal:  Expert Rev Neurother       Date:  2014-11       Impact factor: 4.618

2.  Subchronic administration of (R,S)-ketamine induces ketamine ring hydroxylation in Wistar rats.

Authors:  R Moaddel; M Sanghvi; A Ramamoorthy; K Jozwiak; N Singh; C Green; K O'Loughlin; M Torjman; I W Wainer
Journal:  J Pharm Biomed Anal       Date:  2016-03-14       Impact factor: 3.935

3.  Stereoselective and regiospecific hydroxylation of ketamine and norketamine.

Authors:  Zeruesenay Desta; Ruin Moaddel; Evan T Ogburn; Cong Xu; Anuradha Ramamoorthy; Swarajya Lakshmi Vattem Venkata; Mitesh Sanghvi; Michael E Goldberg; Marc C Torjman; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-05-21       Impact factor: 1.908

4.  Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression.

Authors:  Xiaochen Zhao; Swarajya Lakshmi Vattem Venkata; Ruin Moaddel; Dave A Luckenbaugh; Nancy E Brutsche; Lobna Ibrahim; Carlos A Zarate; Donald E Mager; Irving W Wainer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

5.  Current challenges in translational pain research.

Authors:  Jianren Mao
Journal:  Trends Pharmacol Sci       Date:  2012-09-06       Impact factor: 14.819

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.